IR-Med

IRME · OTC

Price unavailable right now.

No price history for this range.

About IRME

IR-Med, Inc. is engaged in the designing and developing devices utilizing spectrographic usability medical devices based on the combination of Infra-Red (IR) and Artificial Intelligence (AI) technologies. The company is headquartered in New York City, New York and currently employs 3 full-time employees. The company went IPO on 2001-07-18. PressureSafe, the Company’s first product based on this platform, is a handheld device designed to revolutionize the assessment of pressure injuries (PI) affecting skin and underlying tissue. The firm is developing its technology through its subsidiary and is utilizing Infra-Red-light spectroscopy (IR) combined with an artificial intelligence (AI) technology platform to develop non-invasive devices for various medical indications, by assessing various biomarkers and molecules in the blood and in human tissue in real-time. The second product candidate, DiaSafe, which is under development, is a non-invasive, user-friendly device which is designed to address medical needs by offering assessment of Diabetic Foot Ulcer (DFU) before skin breakage.

Employees: 4
Headquarters: New York City, New York
Listed: Jul 18, 2001
Sector: Health Care
Industry: Health Care Equipment & Supplies
Website: ir-medical.com

Leadership

IR-Med executives
Name	Title	Since	Age
Oded Bashan	—	2020	78
Sharon Levkoviz	—	—	51
Aharon Klein	—	2024	64
Ohad Bashan	—	—	54
Yaniv Cohen	—	—	45
Yechiel Even	—	—	76
Ron Mayron	—	—	62
Kathy Cusumano	—	2025	—

Similar companies

Companies in the same industry as IR-Med

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.